[{"orgOrder":0,"company":"T-knife","sponsor":"Fidelity Management & Research Company","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2021","type":"Series B Financing","leadProduct":"TK-8001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"T-knife","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"T-knife \/ Fidelity Management & Research Company","highestDevelopmentStatusID":"7","companyTruncated":"T-knife \/ Fidelity Management & Research Company"},{"orgOrder":0,"company":"T-knife","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2021","type":"Inapplicable","leadProduct":"TK-8001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"T-knife","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"T-knife \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"T-knife \/ Inapplicable"},{"orgOrder":0,"company":"T-knife","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2023","type":"Inapplicable","leadProduct":"TK-8001","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"T-knife","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"T-knife \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"T-knife \/ Inapplicable"},{"orgOrder":0,"company":"T-knife","sponsor":"Versant Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"T-knife","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"T-knife \/ Versant Ventures","highestDevelopmentStatusID":"4","companyTruncated":"T-knife \/ Versant Ventures"},{"orgOrder":0,"company":"T-knife","sponsor":"Catalent Pharma Solutions","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"T-knife","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"T-knife \/ Catalent Pharma Solutions","highestDevelopmentStatusID":"4","companyTruncated":"T-knife \/ Catalent Pharma Solutions"},{"orgOrder":0,"company":"T-knife","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell and Gene therapy","year":"2022","type":"Inapplicable","leadProduct":"TK-2504","moa":"Undisclosed","graph1":"Oncology","graph2":"IND Enabling","graph3":"T-knife","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"T-knife \/ Inapplicable","highestDevelopmentStatusID":"5","companyTruncated":"T-knife \/ Inapplicable"}]